Evidence map›Paper›PMID 35547711›Full record

ArticleRSC advances2018

Antidepressant activity of an aqueous extract from okra seeds.

Fangbo Xia, Chenchen Li, Mengqiu Li, Yonghong Liao, Xinmin Liu, Jianyong Si, Qi Chang, Ruile Pan

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Hypothalamic-Pituitary-Adrenal Axis and Epilepsy.Journal of clinical neurology (Seoul, Korea) · 2024
    Review
  3. Review
  4. Review
  5. Frontiers in nutrition · 2021
    Article
  6. Article
  7. International journal of environmental research and public health · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Fangbo XiaInstitute of Medicinal Plant Development, Peking Union Medical College, Chinese Academy of Medical Sciences No. 151, North Road Malianwa, Haidian District Beijing 100193 PR China rlpan@implad.ac.cn.
Chenchen LiInstitute of Medicinal Plant Development, Peking Union Medical College, Chinese Academy of Medical Sciences No. 151, North Road Malianwa, Haidian District Beijing 100193 PR China rlpan@implad.ac.cn.
Mengqiu LiInstitute of Medicinal Plant Development, Peking Union Medical College, Chinese Academy of Medical Sciences No. 151, North Road Malianwa, Haidian District Beijing 100193 PR China rlpan@implad.ac.cn.
Yonghong LiaoInstitute of Medicinal Plant Development, Peking Union Medical College, Chinese Academy of Medical Sciences No. 151, North Road Malianwa, Haidian District Beijing 100193 PR China rlpan@implad.ac.cn.
Xinmin LiuInstitute of Medicinal Plant Development, Peking Union Medical College, Chinese Academy of Medical Sciences No. 151, North Road Malianwa, Haidian District Beijing 100193 PR China rlpan@implad.ac.cn.
Jianyong SiInstitute of Medicinal Plant Development, Peking Union Medical College, Chinese Academy of Medical Sciences No. 151, North Road Malianwa, Haidian District Beijing 100193 PR China rlpan@implad.ac.cn.ORCID https://orcid.org/0000-0001-7897-2190
Qi ChangInstitute of Medicinal Plant Development, Peking Union Medical College, Chinese Academy of Medical Sciences No. 151, North Road Malianwa, Haidian District Beijing 100193 PR China rlpan@implad.ac.cn.
Ruile PanInstitute of Medicinal Plant Development, Peking Union Medical College, Chinese Academy of Medical Sciences No. 151, North Road Malianwa, Haidian District Beijing 100193 PR China rlpan@implad.ac.cn.ORCID https://orcid.org/0000-0003-3589-9506
Academy of Medical Sciences · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Faced with the increasing incidence of major depression disorder (MDD) and the unsatisfactory effect of current drugs, there has been growing attention on the relation between dietary supplements and MDD prevention. In this research, the antidepressant activity of okra seed extract (OSE) was evaluated with behavioral tests including an open field test, tail suspension test (TST), forced-swimming test (FST) and novelty suppressed feeding test (NSFT) for sub-chronic treatment and chronic sleep-interruption (CSI) animal models. The chemical constituents of OSE were identified by using UPLC-DAD/Q-TOF MS. To investigate the mechanism, the prefrontal cortex and hippocampus were collected to determine neurotransmitters, total antioxidant capacity (T-AOC), superoxide dismutase (SOD) and malondialdehyde (MDA). Blood serum was prepared for the determination of corticosterone (CORT) and adrenocorticotropic hormone (ACTH). Results demonstrated that OSE possessed an antidepressant effect in both sub-chronic treatment and CSI animal models through suppressing the hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis, alleviating oxidative stress and regulating neurotransmitter levels in the hippocampus and frontal cortex. Besides, chemical analysis based on the UPLC-DAD/ESI-Q-TOF MS approach showed that OSE mainly contained catechin and quercetin derivatives. The present study provided a scientific basis for developing okra seeds to be a dietary supplement for MDD prevention.

Identifiers

PMID35547711
PMCPMC9086372
OpenAlexW2889855387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.